EUCTR2006-001916-54-DE进行中（未招募）不适用
A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the Humerus
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 132
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects signed and dated IRB or IEC-approved informed consent form.
- •2. Skeletally mature and aged >= 18 years (closed epiphysis).
- •3. Subjects with a either a closed proximal humeral fracture or a diaphyseal humerus fracture classified as:
- •- Proximal Humeral Fracture (NEER classification): nondisplaced, minimally displaced (<45° angluation and <1cm displaced), 2-Part, 3-Part or 4-Part
- •- Diaphyseal Humeral Fracture (OTA classification): Simple OTA 12-A- Wedge OTA 12-B or Complexe OTA 12-C
- •4. Treatment plan includes only conservative (non-operative) therapy within 48 hours of injury.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Open proximal or humeral shaft fractures.
- •2. Additional planned procedure(s) to stimulate fracture union following application of an initial immobilization device.
- •3. Shoulder dislocation at the time of injury.
- •4. Fractures located in the distal third of the humerus.
- •5. Concurrent fractures of the ipsilateral or contralateral upper extremity that would impede performance on a functional assessment.
- •6. Neurovascular impairment in the region under study.
- •7. Documented history of heterotopic ossification.
- •8. Documented active infection in any anatomical location.
- •9. Retained surgical hardware in the humerus under study due to previous fracture.
- •10. Pathological fractures, except if due to postmenopausal or senile osteoporosis.
- •11. Treatment initiated for osteoporosis within the past 16 weeks.
- •12. Any previous use of therapies that can be considered bone anabolic (parathyroid hormone, growth hormone, anabolic steroids or fluoride at bone therapeutic doses) within the past year.
- •13. History of other metabolic bone disorders that may affect the region under study (eg, Paget's disease, renal osteodystrophy, or benign tumor).
- •14. Documented history of malignancy, except basal or squamous cell carcinoma that has been treated and has fully resolved for a minimum of 5 years.
- •15. History of hypersensivity to rhBMP-2 or to protein pharmaceuticals (such as monoclonal antibodies or gamma globulins).
- •16. Treatment with any investigational therapy within the past 30 days.
- •17. Documented history of ongoing alcohol or drug addiction.
- •18. Any other concurrent condition(s) that, in the judgement of the investigator, would prohibit the subject from participating in the study or hinder the collection of data and interpretation of results (eg, unstable medical condition, life expectancy less than 1 year or inability to comply with required follow-up evaluations).
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the HumerusEUCTR2006-001916-54-FRWyeth Pharmaceuticals Inc.132
进行中（未招募）
1 期
A Phase 2 Clinical Trial to Investigate Safety, Tolerability and Efficacy of TransCon CNP, Weekly Subcutaneous Injections, Compared with Placebo, in Infants with Achondroplasia.Achondroplasia in Children and AdolescentsMedDRA version: 20.0Level: LLTClassification code: 10000452Term: Achondroplasia Class: 10010331CTIS2023-506091-27-00Ascendis Pharma Growth Disorders A/S72
进行中（未招募）
1 期
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with primary proteinuric renal diseasePrimary glomerular disease and persistent proteinuriaMedDRA version: 20.1Level: PTClassification code 10037032Term: ProteinuriaSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-006579-41-LTAngion Biomedica Corp.100
进行中（未招募）
不适用
A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the HumerusEUCTR2006-001916-54-FIWyeth Pharmaceuticals Inc.132
进行中（未招募）
不适用
A Phase 2, Multicenter, Double-Blind, Randomized, Stratified, Controlled, Efficacy, Safety and Feasibility Study of rhBMP-2/CPM as an Adjuvant Therapy in Closed Fractures of the HumerusClosed Fractures of the HumerusMedDRA version: 8.1Level: LLTClassification code 10017127Term: Fracture of humerusEUCTR2006-001916-54-SEWyeth Pharmaceuticals Inc.132